| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c18019d16f8ccb50123e744a5b59e60e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_951043b3dd8f547029dcdaa55da84c4e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9ab2575af998fd33c67283fe8fc40ef5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_82720f0fe09c6d788db8fde9be2350dc |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0004
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0056 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0004
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-087
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0041
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0032
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B10-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B8-00 |
| filingDate |
2008-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2014-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9c1c7011088ddff468ceb7b6ee731bc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b42a918911f6949b8909bd7f476c9c6f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8df309ca9dae0b6c3eeb1a30283e4f3f |
| publicationDate |
2014-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8771645-B2 |
| titleOfInvention |
Composition comprising a cell death marker and a wavelength-optimized label |
| abstract |
The invention relates to the use of a cell death marker labelled with a wavelength-optimised label for identifying cell death in the eye. Suitable cell death markers are the Annexins and fragments and derivatives thereof. The invention also relates to a pharmaceutical composition comprising a cell death marker labelled with a wavelength-optimised label and a method for monitoring cell death in the eye using a cell death marker labelled with a wavelength-optimised label. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10343730-B2 |
| priorityDate |
2007-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |